In EGFR wild-type NSCLC cells, CD44 inhibition attenuated cell growth, promoted cell cycle arrest, stimulated cell apoptosis, and enhanced sensitivity to cisplatin [168]. This evidence concerns the gene CD44 and non-small cell lung carcinoma.